Wai Man Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1005016/publications.pdf

Version: 2024-02-01

394421 377865 1,232 47 19 34 citations h-index g-index papers 48 48 48 1783 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. British Journal of Cancer, 2010, 102, 115-123.	6.4	294
2	The Combination of Cannabidiol and Î"9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model. Molecular Cancer Therapeutics, 2014, 13, 2955-2967.	4.1	117
3	Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Molecular Cancer Therapeutics, 2006, 5, 1197-1208.	4.1	93
4	Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood, 2005, 105, 1214-1221.	1.4	67
5	The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. International Journal of Cancer, 2011, 128, 1471-1480.	5.1	57
6	Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration. International Journal of Oncology, 2017, 51, 369-377.	3.3	56
7	Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene, 2004, 23, 981-990.	5.9	55
8	In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemotherapy and Pharmacology, 2011, 67, 569-577.	2.3	46
9	Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). British Journal of Cancer, 2009, 101, 803-812.	6.4	39
10	Enhancing the <i>in vitro</i> cytotoxic activity of î" ⁹ -tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leukemia and Lymphoma, 2008, 49, 1800-1809.	1.3	37
11	A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro. Molecular Biology Reports, 2010, 37, 1801-1814.	2.3	29
12	Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy. International Journal of Oncology, 2016, 49, 793-802.	3.3	26
13	Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Research, 2015, 35, 5827-37.	1.1	26
14	The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. British Journal of Cancer, 2002, 86, 1472-1478.	6.4	24
15	Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules. Anticancer Research, 2013, 33, 4373-80.	1.1	23
16	Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti-Inflammatory Role for the Cannabinoids. Current Clinical Pharmacology, 2010, 5, 281-287.	0.6	21
17	Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?. Current Clinical Pharmacology, 2008, 3, 108-117.	0.6	20
18	Methylene Homologues of Artemisone: An Unexpected Structure–Activity Relationship and a Possible Implication for the Design of C10â€Substituted Artemisinins. ChemMedChem, 2016, 11, 1469-1479.	3.2	20

#	Article	IF	CITATIONS
19	s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. The Hematology Journal, 2004, 5, 247-254.	1.4	19
20	The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Cancer Chemotherapy and Pharmacology, 2003, 51, 291-296.	2.3	17
21	Diaminofluorene stain detects erythroid differentiation in immature haemopoietic cells treated with EPO, IL-3, SCF, TGFβ1, MIP-1α and IFNγ. European Journal of Haematology, 2003, 70, 106-114.	2.2	14
22	A Comparison of the Platinum Analogues in Bladder Cancer Cell Lines. Urologia Internationalis, 2007, 79, 67-72.	1.3	14
23	MTT assays can underestimate cell numbers. Cancer Chemotherapy and Pharmacology, 2009, 64, 861-862.	2.3	13
24	Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines. Leukemia, 2002, 16, 1705-1712.	7.2	12
25	The Potential Beneficial Effects of Drugs on the Immune Response to Vaccination. Seminars in Oncology, 2012, 39, 340-347.	2.2	10
26	The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. FEBS Journal, 2004, 271, 2773-2781.	0.2	9
27	Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet, The, 2004, 363, 82.	13.7	9
28	Supernatants derived from chemotherapy-treated cancer cell lines can modify angiogenesis. British Journal of Cancer, 2012, 106, 896-903.	6.4	8
29	The gene expression profile of unstimulated dendritic cells can be used as a predictor of function. International Journal of Cancer, 2012, 130, 979-990.	5.1	8
30	Diamond Blackfan anaemia: differential pattern of in vitro progenitor response to macrophage inflammatory protein 1â€alpha. British Journal of Haematology, 1996, 92, 280-286.	2.5	7
31	Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses. British Journal of Cancer, 2011, 105, 687-693.	6.4	7
32	Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. Medical Oncology, 2010, 27, 430-433.	2.5	6
33	Dendritic cell phenotype can be improved by certain chemotherapies and is associated with alterations to p21waf1/cip1. Cancer Immunology, Immunotherapy, 2013, 62, 1553-1561.	4.2	5
34	A novel approach to investigating the erythroid lineage, using both receptor analysis and haemoglobin detection. British Journal of Haematology, 1996, 95, 457-460.	2.5	3
35	Effects of haemopoietic growth factors in combination with etoposide on sister chromatid exchange frequencies in peripheral blood mononuclear cells. Cancer Chemotherapy and Pharmacology, 1998, 41, 343-346.	2.3	3
36	Cannabinoids: Do they have a Role in Cancer Therapy?. Letters in Drug Design and Discovery, 2006, 3, 76-82.	0.7	3

#	Article	IF	CITATIONS
37	Recent Developments in the Understanding of Nuclear Protein Import. Protein and Peptide Letters, 2007, 14, 723-733.	0.9	3
38	A heat-killed preparation of mycobacterium obuense can reduce metastatic burden in vivo. , $2014, 2, P54$.		3
39	Cancer cell-derived supernatants that support the carcinogenic process: a future cancer therapy target?. Future Oncology, 2012, 8, 767-769.	2.4	2
40	Abstract 5612: Pretreatment with chemotherapy can enhance the immunogenicity of tumors by promoting adaptive immune responses. Cancer Research, 2010, 70, 5612-5612.	0.9	2
41	The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy. Current Signal Transduction Therapy, 2009, 4, 122-129.	0.5	2
42	Recent Advances and Developments in the Inhibitors of DNA Topoisomerases. Current Enzyme Inhibition, 2007, 3, 161-174.	0.4	1
43	The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agents. Oncology Letters, 2020, 20, 1-1.	1.8	1
44	Supernatants of tumours treated with chemotherapy can alter tumour growth and development in vivo. Anticancer Research, 2015, 35, 1499-508.	1.1	1
45	Re: Loss of DNA Mismatch Repair: Effects on the Rate of Mutation to Drug Resistance. Journal of the National Cancer Institute, 1998, 90, 246-246.	6.3	0
46	Antiapoptotic Effect of Growth Factors in Leukemia. Journal of Clinical Oncology, 2005, 23, 649-649.	1.6	0
47	The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agents. Oncology Letters, 2020, 20, 321.	1.8	O